EVOLOCUMAB IS ASSOCIATED WITH LOWER MORTALITY WHEN COMPARED TO STATIN IN MASLD/MASH PATIENTS: A MULTINATIONAL ANALYSIS

Authors

Donghyun Ko, Department of Internal Medicine, Bridgeport Hospital, Yale New Haven Health, Bridgeport, CT, USA.Follow
Do Han Kim MD, Department of Medicine, Mount Sinai Morningside and West, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Wilhelm S. Basegoda MD, University of South Alabama, Mobile, AL, USA
Jose A. Porres, Universidad Francisco Marroquin, Guatemala City, Guatemala.
Cristina H. Makarian, Universidad Francisco Marroquín, Facultad de Medicina, Guatemala City, Guatemala
Luis M. Nieto MD, Division of Gastroenterology and Hepatology, Emory University, Atlanta, GA, USA.
Pedro Palacios Argueta MD, Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital, Philadelphia, PA, USA
Paul T. Kroner MD, Department of Gastroenterology, Riverside Health System, Newport News, VA, USA.
Frank J. Lukens MD, Division of Gastroenterology and Hepatology, Mayo Clinic Florida, Jacksonville, FL, USA

Document Type

Conference Proceeding

Abstract

Evolocumab is typically used as an add-on or replacement therapy for patients with dyslipidemia who are already on the maximum tolerated dose of statins or are intolerant to statins. While statins are effective in lowering lipid levels and have been shown to improve liver-related outcomes and reduce major adverse cardiovascular events (MACE), statin intolerance is increasingly encountered with their widespread use. The aim of our study is to compare the benefits of using evolocumab as monotherapy versus statins as monotherapy in patients with metabolic-dysfunction-associated steatotic liver disease (MASLD) and metabolic-dysfunction-associated steatohepatitis (MASH).

Publication Date

5-2025

Recommended Citation

Ko, Donghyun; Kim, Do Han MD; Basegoda, Wilhelm S. MD; Porres, Jose A.; Makarian, Cristina H.; Nieto, Luis M. MD; Palacios Argueta, Pedro MD; Kroner, Paul T. MD; and Lukens, Frank J. MD, "EVOLOCUMAB IS ASSOCIATED WITH LOWER MORTALITY WHEN COMPARED TO STATIN IN MASLD/MASH PATIENTS: A MULTINATIONAL ANALYSIS" (2025). Posters. 100.
https://scholar.bridgeporthospital.org/poster_presentations/100